| Title |
The role of dolutegravir in the management of HIV infections
|
|---|---|
| Published in |
Infection and Drug Resistance, February 2015
|
| DOI | 10.2147/idr.s58706 |
| Pubmed ID | |
| Authors |
Misty M Miller, Michelle D Liedtke, Staci M Lockhart, R Chris Rathbun |
| Abstract |
Dolutegravir is the most recent integrase strand transfer inhibitor approved for HIV-1 infection in both treatment-naïve and experienced patients. As a tricyclic carbamoyl pyridone analog, dolutegravir is rapidly absorbed and distributes through the cerebrospinal fluid. It is hepatically metabolized by uridine diphosphate glucuronosyl transferase 1A1; no inhibition or induction of cytochrome P450 enzymes is noted. As a substrate of CYP 3A4, dolutegravir is affected by rifampin, efavirenz, tipranavir/ritonavir, fosamprenavir/ritonavir, and dose increase is required. Dolutegravir inhibits the organic cation transporter 2, resulting in decreased creatinine clearance with no apparent decrease in renal function. Other adverse effects are minimal but include diarrhea, headache, and nausea. Clinical trials in treatment-naïve and experienced patients are ongoing and will be presented in this text. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Venezuela, Bolivarian Republic of | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 56 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 56 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 9 | 16% |
| Student > Bachelor | 6 | 11% |
| Other | 5 | 9% |
| Student > Postgraduate | 5 | 9% |
| Student > Ph. D. Student | 4 | 7% |
| Other | 7 | 13% |
| Unknown | 20 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 34% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 13% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Immunology and Microbiology | 2 | 4% |
| Nursing and Health Professions | 1 | 2% |
| Other | 5 | 9% |
| Unknown | 19 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 October 2023.
All research outputs
#5,863,638
of 23,275,636 outputs
Outputs from Infection and Drug Resistance
#202
of 1,725 outputs
Outputs of similar age
#78,639
of 354,978 outputs
Outputs of similar age from Infection and Drug Resistance
#3
of 4 outputs
Altmetric has tracked 23,275,636 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 1,725 research outputs from this source. They receive a mean Attention Score of 3.9. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 354,978 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.